Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection

Journal of Urology

Volumn 182, Issue 6, 2009, Pages 2653-2658

  Eyre, Stephen J ^a   Ankerst, Donna P ^d,e   Wei, John T ^f   Nair, Prakash V ^e   Regan, Meredith M ^b,c   Bueti, Gerrardina ^a   Tang, Jeffrey ^a   Rubin, Mark A ^g   Kearney, Michael ^a   Thompson, Ian M ^e   Sanda, Martin G ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

biological markers; clinical trials as topic; early detection of cancer; mass screening; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALIBRATION; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

AGED; BIOPSY; FORECASTING; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 71849102519     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.056     Document Type: Article

References (23)

1. Andriole G.L., Crawford D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310
2. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320
3. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909
4. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156
5. Punglia R.S., D'Amico A.V., Catalona W.J., et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349 (2003) 335
6. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
7. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
8. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837
9. Cox D.R. Two further applications of a model for binary regression. Biometrika 45 (1988) 562
10. Miller M.E., Hui S.L., and Tierney W.M. Validation techniques for logistic regression models. Stat Med 10 (1991) 1213
11. Thompson I.M., Pauler Ankerst D., Chi C., et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol 25 (2007) 3076
12. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 (2005) 433
13. van den Bergh R.C., Roobol M.J., Wolters T., et al. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int 102 (2008) 1068
14. Shariat S.F., Karakiewicz P.I., Margulis V., et al. Inventory of prostate cancer predictive tools. Curr Opin Urol 18 (2008) 279
15. Karakiewicz P.I., Benayoun S., Kattan M.W., et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 173 (2005) 1930
16. Chun F.K., Briganti A., Graefen M., et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 52 (2007) 436
17. Porter C.R., Gamito E.J., Crawford E.D., et al. Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting. Urology 65 (2005) 937
18. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
19. Parekh D.J., Ankerst D.P., Higgins B.A., et al. External validation of the Prostate Cancer Prevention Trial risk calculator. Urology 68 (2006) 1152
20. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542
21. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215
22. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
23. Etzioni R.D., Ankerst D.P., Weiss N.S., et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer?. A critical appraisal of the evidence. J Natl Cancer Inst 99 (2007) 1510